Science 37 Appoints Tyler Van Horn as CEO to Lead Next Era of Patient-Access Innovation

Company Overview - Science 37 has appointed Tyler Van Horn as Chief Executive Officer, previously serving as Chief Commercial Officer, credited with driving operational excellence and strategic direction [1][2] - The company focuses on enhancing patient access to clinical trials, aiming to solve patient enrollment and study conduct challenges for clinical research clients [2][3] Leadership Vision - Van Horn emphasizes the importance of enabling therapies to reach endpoints faster, gaining approvals, and ensuring equitable health outcomes [3] - The commitment to expanding patient access is central to Science 37's mission, particularly in reaching underserved populations [3] Strategic Direction - Van Horn's leadership is expected to build upon past successes and enhance the company's growth through innovation and improved solution delivery [3] - Science 37 aims to lead in accessibility, diversity, and patient safety within the clinical research sector [3]